Approval Time : Sept. 14, 2017
Direct Target : TUBB1,TUBA4A
Drug Type : Single-target inhibitor
Indications : Cabazitaxel was approved at the lower dose of 20 mg/m2 every 3 weeks in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen.
Mechanism Of Action :
Cabazitaxel is a microtubule inhibitor. Cabazitaxel binds to tubulin and promotes its assembly into microtubules while simultaneously inhibiting disassembly. This leads to the stabilization of microtubules, which results in the inhibition of mitotic and interphase cellular functions.
Dosage : The recommended dose of cabazitaxel is now 20 mg/m2 administered every three weeks as a one-hour intravenous infusion in combination with oral prednisone 10 mg administered daily. A dose of 25 mg/m2 can be used in select patients at the discretion of the treating health-care provider.
Related Targets and Diseases
| Drug Name |
Gene |
|
Disease |
|
Negative Genotypes |
Drug Brand |
|
Drug Type |
|
